Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour

International Journal of Radiation Biology

Volumn 78, Issue 5, 2002, Pages 407-415

  Flynn, A A ^a   Pedley, R B ^a   Green, A J ^a   Boxer, G M ^a   Boden, R ^a   Bhatia, J ^a   Morris, R ^a   Begent, R H J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A5B7; MONOCLONAL ANTIBODY DFM; MONOCLONAL ANTIBODY MFE 23; MONOCLONAL ANTIBODY MOPC; MONOCLONAL ANTIBODY NFE; MONOCLONAL ANTIBODY TFM; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; RADIOSENSITIVITY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; COLORECTAL NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIATION TOLERANCE; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; YTTRIUM RADIOISOTOPES;

ANIMALIA; MUS MUSCULUS;

EID: 0036253055     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/09553000110117818     Document Type: Article

References (35)

1. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
2. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: Beta dosimetry of small spheres
3. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice
4. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptide G2 fusion protein
5. Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)-implications for targeted therapy
6. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments
7. Phage libraries for generation of clinically useful antibodies
8. Factors affecting 131-I-Lynn-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia
9. A novel technique, using radioluminography, for the measurement of uniformity of radiolabeled antibody distribution in a colorectal cancer xenograft model
10. A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology
11. 90Y labelled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumour
12. The effectiveness of radiolabelled antibodies for radioimmunotherapy in a colorectal xenograft model: A comparative study using the linear-quadratic formulation
13. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,6,6-tetrachloro-3a, 6a-diphenylglycoluril
14. 131I-labelled human growth hormone of high specific radioactivity
15. Mapping epitope characteristics on carcinoembryonic antigen
16. Nonuniformity of tumor dose in radioimmunotherapy
17. Barriers to drug delivery in solid tumors
18. Transport of molecules in the tumor interstitium: A review
19. Mechanisms of heterogeneous distribution of monoclonal antibodies in tumors: Significance of elevated interstitial pressure
20. Improved tumor targeting with chemically cross-linked recombinant antibody fragments
21. Tumor-absorbed-dose estimates versus response in tositumab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report
22. 2 antibodies
23. Efficacy and safety of 131-I metaiodobenzylguanaide therapy for patients with refractory neuroblastoma
24. Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: Relevance to microdosimetry
25. A new approach to modelling the formation of necrotic regions in tumors
26. Phase II trial of 131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
27. 99mTc labelling of MFE-23 (an anti-CEA single chain antibody)
28. Reconciliation of tumor response to external beam radiotherapy versus radioimmunotherapy with 131 Iodine-labeled antibody for a colon cancer model
29. Immunotherapy of human ovarian carcinoma with OVARIX™ Mab-B43.13 in a human-PBL-SCID/BG mouse model
30. Plasmapheresis in radioimmunotherapy of microtastases: A mathematical modeling and dosimetrical analysis
31. Pharmacokinetyic modeling
32. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody of ligand: A biomathematical model
33. Human colonic adenocarcinoma cells
34. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts
35. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms